These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6505385)

  • 1. Central serotonin antagonist activity of ketanserin.
    Fuller RW; Snoddy HD
    Res Commun Chem Pathol Pharmacol; 1984 Oct; 46(1):151-4. PubMed ID: 6505385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of a difference between ketanserin and ritanserin in central vs. peripheral serotonin receptor antagonism.
    Cohen ML; Bloomquist WL; Snoddy HD; Fuller RW
    Life Sci; 1989; 45(13):1185-9. PubMed ID: 2507847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flumezapine, an antagonist of central dopamine and serotonin receptors.
    Fuller RW; Mason NR
    Res Commun Chem Pathol Pharmacol; 1986 Oct; 54(1):23-34. PubMed ID: 2879325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptation of brain 5HT2 receptors after mianserin treatment: receptor sensitivity, not receptor binding, more accurately correlates with behavior.
    Smith RL; Barrett RJ; Sanders-Bush E
    J Pharmacol Exp Ther; 1990 Aug; 254(2):484-8. PubMed ID: 2166792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin receptor subtypes involved in the elevation of serum corticosterone concentration in rats by direct- and indirect-acting serotonin agonists.
    Fuller RW; Snoddy HD
    Neuroendocrinology; 1990 Aug; 52(2):206-11. PubMed ID: 2148812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The specificity of ketanserin in the inhibition of serotonin-induced steroidogenesis in the rat adrenal zona glomerulosa.
    Williams BC; Shaikh S; Edwards CR
    J Hypertens Suppl; 1984 Dec; 2(3):S559-61. PubMed ID: 6100754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat.
    Lucki I; Nobler MS; Frazer A
    J Pharmacol Exp Ther; 1984 Jan; 228(1):133-9. PubMed ID: 6694097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor.
    Smith RL; Barrett RJ; Sanders-Bush E
    J Pharmacol Exp Ther; 1995 Nov; 275(2):1050-7. PubMed ID: 7473132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonism of a peripheral vascular but not an apparently central serotonergic response by xylamidine and BW 501C67.
    Fuller RW; Kurz KD; Mason NR; Cohen ML
    Eur J Pharmacol; 1986 Jun; 125(1):71-7. PubMed ID: 3732393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212.
    Hemrick-Luecke SK; Fuller RW
    Eur J Pharmacol; 1996 Sep; 311(2-3):207-11. PubMed ID: 8891601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three distinct subtypes of serotonergic receptors mediate the triphasic blood pressure response to serotonin in rats.
    Kalkman HO; Engel G; Hoyer D
    J Hypertens Suppl; 1984 Dec; 2(3):S143-5. PubMed ID: 6599662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of metergoline and other serotonin receptor antagonists on serum corticosterone in rats.
    Fuller RW; Snoddy HD
    Endocrinology; 1979 Oct; 105(4):923-8. PubMed ID: 477605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate.
    Fuller RW; Snoddy HD
    Res Commun Chem Pathol Pharmacol; 1992 Jul; 77(1):87-93. PubMed ID: 1359615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quipazine reduces food intake in the rat by activation of 5-HT2-receptors.
    Hewson G; Leighton GE; Hill RG; Hughes J
    Br J Pharmacol; 1988 Oct; 95(2):598-604. PubMed ID: 2906561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological evidence for a role of brain serotonin in the maintenance of plasma renin activity in unanesthetized rats.
    Van de Kar LD; Wilkinson CW; Ganong WF
    J Pharmacol Exp Ther; 1981 Oct; 219(1):85-90. PubMed ID: 6457138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. pH-dependent modulation of agonist interactions with [3H]-ketanserin-labelled S2 serotonin receptors.
    Battaglia G; Shannon M; Borgundvaag B; Titeler M
    Life Sci; 1983 Nov; 33(20):2011-6. PubMed ID: 6645787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites.
    Friedman RL; Barrett RJ; Sanders-Bush E
    J Pharmacol Exp Ther; 1984 Mar; 228(3):628-35. PubMed ID: 6707913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the mechanism of action of ketanserin, a selective antagonist of the S2 receptors with antihypertensive activity.
    Rión R; Mena MA; Hong E
    Proc West Pharmacol Soc; 1983; 26():373-5. PubMed ID: 6889366
    [No Abstract]   [Full Text] [Related]  

  • 19. Serotonin type 2 antagonists inhibit lordosis behavior in the female rat: reversal with quipazine.
    Mendelson SD; Gorzalka BB
    Life Sci; 1986 Jan; 38(1):33-9. PubMed ID: 2934598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats.
    Cohen ML; Fuller RW; Kurz KD
    Hypertension; 1983; 5(5):676-81. PubMed ID: 6311738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.